Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05916196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

[18F]FES PET/.CT in Uterine Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 1, 2026 to Aug 1, 2027 Completion date: Aug 1, 2027 to Aug 1, 2028v5 Show 1 more changeShow less
    • Completion date: Aug 1, 2027 to Aug 1, 2028
  2. Primary completion date: Aug 1, 2025 to Aug 1, 2026 Start date: Sep 1, 2023 to Apr 5, 2024 · Completion date: Aug 1, 2026 to Aug 1, 2027v4 Show 2 more changesShow less
    • Start date: Sep 1, 2023 to Apr 5, 2024
    • Completion date: Aug 1, 2026 to Aug 1, 2027
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 1, 2023 to Sep 1, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 1, 2023 to Sep 1, 2023
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. \[18F\]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET/CT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET/CT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy). The selection of therapy will be made by a treating physician and will not be affected by participation in this imaging study. Results of the FES PET/CT scan may be shared with the treating physician or subject by request but will not be used to make clinical decisions about treatment.
Trial Details
NCT Number NCT05916196
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Uterine Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov